The objective of this study is to provide critical information regarding both common and distinctive roles of EPA and DHA in systemic inflammation and lipid metabolism.
This is a randomized, placebo-controlled, double-blind, crossover study of the effects of EPA and DHA on inflammation and lipid metabolism in 24 men and women with metabolic syndrome. The study will characterize the effects of EPA alone and DHA alone, relative to each other and to placebo, on plasma biomarkers of inflammation, inflammatory cell activation and gene expression, and plasma lipid and lipoprotein levels.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
24
10 week supplementation
10 week supplementation
4-week lead-in
Jean Mayer Human Nutrition Research Center on Aging at Tufts University
Boston, Massachusetts, United States
Interleukin-6 (IL-6)
plasma levels in pg/mL
Time frame: 10 weeks
Tumor Necrosis Factor Alpha (TNF-alpha)
plasma levels in pg/mL
Time frame: 10 weeks
Low Density Lipoprotein Cholesterol (LDL-C)
plasma levels in mg/dL
Time frame: 10 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.